TL;DR
Prime made for students and young adults
- Fast, free delivery for dorm and study essentials
- Prime Video and Amazon Music included
- Member-only deals
CAR T cell therapy, originally approved for blood cancers, is now being tested as a treatment for autoimmune diseases. Early results are promising, but long-term effects and safety remain uncertain. This could transform how autoimmune conditions are treated.
Clinical trials of CAR T cell therapy, a treatment originally approved for certain blood cancers, are showing promising results in treating autoimmune diseases, including multiple sclerosis and lupus.
CAR T cell therapy involves modifying a patient’s immune cells to target specific cells causing disease. While it was first approved by the FDA in 2017 for leukemia, researchers are now exploring its potential to reset immune systems in autoimmune conditions. In recent trials, patients with conditions like lupus and stiff person syndrome have experienced significant symptom relief, with some able to stop other immunotherapies. For example, a study led by Amanda Piquet at the University of Colorado reported that all 26 participants with stiff person syndrome no longer used additional immunotherapies up to 12 months after treatment, and many regained mobility. These early results suggest CAR T could offer a long-lasting solution, but long-term safety and effectiveness are still being studied.
Why It Matters
If proven safe and effective, CAR T therapy could revolutionize treatment for autoimmune diseases, which currently rely on lifelong immunosuppressants with significant side effects. This approach has the potential to provide a one-time, durable treatment, reducing disease burden and improving quality of life for millions worldwide.
Popular right now
Dyson Cyclone V10 Origin Cordless Vacuum
KitchenAid Artisan 5-Quart Tilt-Head Stand Mixer, Almond Cream
Bose QuietComfort True Wireless Earbuds with Active Noise Cancellation, Black
As an affiliate, we earn on qualifying purchases.
Background
CAR T cell therapy was first approved in 2017 for certain leukemias, with subsequent success in blood cancers. Its application to autoimmune diseases is a recent development, with pioneering studies beginning around 2021. Early trials have demonstrated that targeting B cells can alleviate symptoms, but long-term data is limited. The approach aims to eliminate the immune cells responsible for attacking normal tissues, effectively resetting immune function.
“I think it’s a game changer for autoimmune diseases.”
— Amanda Piquet, autoimmune neurologist at the University of Colorado
“Patients have shown remarkable improvements, but long-term data is still needed.”
— Research team at the University of Nebraska Medical Center
What Remains Unclear
It is not yet clear how durable the benefits of CAR T therapy will be for autoimmune diseases, nor what long-term side effects might emerge. Larger, longer-term studies are ongoing to address these questions.
What’s Next
Further clinical trials are planned to evaluate safety, optimal dosing, and long-term efficacy. Regulatory agencies will review additional data before considering broader approval for autoimmune indications.
Key Questions
How does CAR T cell therapy work for autoimmune diseases?
It involves modifying a patient’s T cells to target and eliminate immune cells responsible for attacking normal tissues, potentially resetting the immune system.
What are the risks associated with CAR T therapy in autoimmunity?
Potential risks include severe inflammation, long-term immune suppression, and unknown side effects, which are still being studied.
When might this treatment become widely available?
It remains uncertain; further clinical trials are needed, and regulatory approval processes could take several years.
Can CAR T therapy cure autoimmune diseases?
While early results are promising, it is too soon to say whether it can provide a permanent cure. Ongoing research aims to determine the durability of benefits.
